Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulzer Changes Name To Centerpulse, Will Approve Class Settlement May 22

This article was originally published in The Gray Sheet

Executive Summary

Sulzer Medica will attempt to reduce the financial impact of 132 opt-out cases from its class action settlement, reiterating that the firm may file for Chapter 11 bankruptcy to avoid settling those claims

You may also be interested in...



Zimmer Contacting Physicians Over Hip Implant Fracture Reports In Europe

Zimmer has sent "Dear Doctor" letters to orthopedic surgeons who have used the firm's ZMR hip stem prostheses after several reports of implant fractures

Zimmer Contacting Physicians Over Hip Implant Fracture Reports In Europe

Zimmer has sent "Dear Doctor" letters to orthopedic surgeons who have used the firm's ZMR hip stem prostheses after several reports of implant fractures

Financings In Brief

LipoScience IPO: Sale of 5 mil. shares in $80 mil. initial public offering is postponed Sept. 19. The maker of the NMR LipoProfile cardiovascular disease risk assessment test planned on pricing each share at $14-16 (1"The Gray Sheet" March 11, 2002, p. 18). The IPO, which originally had been targeted to raise $100 mil., was delayed following the stock market downturn the week of Sept. 16. The NMR LipoProfile is more expensive than traditional, standard-of-care cholesterol tests, which may have contributed to investor jitters...

Related Content

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel